Recent ultrasensitive assays have enabled the measurement of GFAP in serum; studies have found that serum GFAP is higher in progressive MS patients compared to those with relapsing–remitting MS, and higher GFAP associates it with more advanced disease [12,17]. Here, GFAP is linked to myeloid sarcoma.